ACLX

Arcellx, Inc. operates as a clinical-stage biotechnology company focused on developing cell therapies for cancer treatment. Headquartered in Gaithersburg, Maryland, the company specializes in its proprietary ARC-SparX platform, which engineers T cells using synthetic binder technology to target specific disease antigens. The company's lead product candidate, ACLX-001 (imsatokimab), is a D-domain-enabled CAR-T therapy targeting BCMA for the treatment of relapsed or refractory multiple myeloma. Arcellx is advancing this candidate through pivotal clinical trials, with the Phase 2 iMMagine-1 study demonstrating promising efficacy and safety data. The company also develops ACLX-002, a CAR-T therapy targeting CD19 for B-cell malignancies. Founded in 2014, Arcellx went public in February 2022 and maintains strategic partnerships with Kite Pharma, a Gilead company, which holds global development and commercialization rights to ACLX-001 outside the United States. The collaboration provides Arcellx with milestone payments and royalties while Kite manages international commercialization efforts. The company retains full U.S. rights to its product candidates and continues to advance its pipeline of additional D-domain-based therapies. Arcellx employs approximately 150 people and operates research facilities focused on advancing next-generation cell therapy technologies that aim to improve outcomes for patients with difficult-to-treat cancers.